TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06090084

Intervention type: OTHER
Intervention: Evaluation
Description: Functional capacity, balance, core muscle strength, trunk muscle structure, lower extremity muscle strength, upper extremity functions, fatigue and respiratory muscle strength will be evaluated.

Intervention type: OTHER
Intervention: Evaluation
Description: Functional capacity, balance, core muscle strength, trunk muscle structure, lower extremity muscle strength, upper extremity functions, fatigue and respiratory muscle strength will be evaluated.
Study: NCT06076902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff reconstruction using fixation with anchors augmented with a synthetic polyester patch (Pitch-Patch Tissue Reinforcement Device))
Description: The Pitch-Patch is a single-use device intended to reinforce the rotator cuff following or during repair by sutures or suture anchors where weakness exists in the soft tissue.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic rotator cuff reconstruction using fixation with anchors augmented without a synthetic polyester patch
Description: Arthroscopic rotator cuff reconstruction using fixation with anchors and no augmentation with a synthetic polyester patch.
Study: NCT06442735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intrapartum ultrasound
Description: In IPUS group, the patient's labor was observed by intrapartum ultrasound.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vaginal examination
Description: In VE group, the patient's labor was observed by vaginal examination.
Study: NCT06072417

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Assessment without intervention at High altitude
Description: Assessments at High altitude corresponding to Baseline measures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relocation to sea level for 2 days
Description: Participants will be relocated to sea level and intervention and have assessements there.
Study: NCT05681702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin plus clopidogrel
Description: After at least 30 days of DAPT \[with aspirin 81-mg od and a potent P2Y12 inhibitor (prasugrel 10 mg od or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will continue aspirin and switch to clopidogrel 75-mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel or ticagrelor
Description: After at least 30 days of DAPT \[with aspirin 81-mg od and a potent P2Y12 inhibitor (prasugrel 10 mg od or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will drop aspirin and continue prasugrel or ticagrelor.
Study: NCT04705259

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Antimicrobial Stewardship ENGAGEMENT bundle
Description: Given that a single intervention is unlikely to be effective in stewardship programs, nor in care improvement processes at RACFs \[7\], this trial will deliver a set of multimodal, multidisciplinary interventions to optimise antibiotic use in RACFs. This RACF AMS ENGAGEMENT bundle will comprise the following key interventions:~* Education and engagement of prescribers, nurses, pharmacists and residents and family members~* Nursing initiatives to improve UTI diagnosis and reduce inappropriate urine testing~* Guideline development specific to antibiotic use in RACF residents~* Antimicrobial stewardship team creation in RACF with GP involvement~* EMergency department liaison and use of clinical pathways to ensure consistency of practice across the care continuum~* ElectroNic decision support to guide RACF urine testing and GP antibiotic prescribing~* Telehealth support for key intervention components
Study: NCT06078436

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary artery catheter
Description: Pulmonary artery catheter monitoring or not

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter
Description: Pulmonary artery catheter monitoring or not
Study: NCT05678634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Declarative learning with immediate feedback
Description: Children will complete a paired associate learning task on a computer. Each response on half of the blocks will be followed by performance feedback. Feedback will be provided 500 ms following a response (button press)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Declarative learning with delayed feedback
Description: Children will complete a paired associate learning task on a computer. Each response on half of the blocks will be followed by performance feedback. Feedback will be provided 5000 ms following a response (button press)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Probabilistic learning with immediate feedback
Description: Children will complete a probabilistic learning task on a computer. Each response on half of the blocks will be followed by feedback. Feedback will be provided 500 ms following a response (button press)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Probabilistic learning with delayed feedback
Description: Children will complete a probabilistic learning task on a computer. Each response on half of the blocks will be followed by feedback. Feedback will be provided 5000 ms following a response (button press)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Word learning task with active feedback
Description: Children will complete a two-choice nonword learning task in which they will be tasked with learning to associate novel objects with novel nonword names through trial and error guided by feedback. Each response will be followed by feedback either indicating that the response is correct or prompting the child to try again (i.e., to correct an error)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Word learning task with passive feedback
Description: Children will complete a two-choice nonword learning task in which they will be tasked with learning to associate novel objects with novel nonword names. Regardless of response accuracy on each trial, each response will be followed by a visual presentation of the correct response.
Study: NCT06196606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A for injection
Description: Botulinum toxin was injected into the upper esophageal sphincter of each patient
Study: NCT05542758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total Body HIIT Program
Description: One repetition maximums (1RM) and body weight (BW) will be recorded at prior to and at 6 weeks to tailor the program. The circuit will be completed twice during each session and the exercises will include: squats, medicine ball forward chest throws, medicine ball overhead throw, farmers walk, seated shoulder press, seated row sitting on a fitness ball, aerobic riser step-ups, foot ladder drills, and twisting medicine ball passes. The anaerobic component will be completed once during a session and on a stationary bike. The progression of exercise:rest seconds will be 20:40 for Weeks 1-4, 30:30 for Weeks 5-8, and 40:20 for Weeks 9-12. Each session will start with a 5 minute warm up and end with a 5-minute cool down. Participants will be given real time feedback about heart rate (goal range: 85-95% HRmax) and exercise movement velocity. Participants will be encouraged to surpass the velocity of the previous repetition.
Study: NCT05487261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan
Description: level 1-24 / 26mg 2 times a day, level 2-49 / 51mg 2 times a day, level 3-97 / 103mg 2 times aday

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: level 1-2.5 mg twice a day, level 2-5 mg twice a day, level 3-10 mg twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo matching for 24 / 26mg, 49 / 51mg, 97 / 103mg 2 of sacubitril/valsartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo matching for 2.5 mg, 5 mg, 10 mg of enalapril
Study: NCT06244667

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: facet median block with prilocain
Description: facet median block with prilocain

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: facet median block with lidocaine
Description: facet median block with lidocaine
Study: NCT04971356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg for 1-month (immediately after PCI)
Description: Aspirin for 1-month immediately after PCI to be a part of medication treatment in the Experimental arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg for 6-month (immediately after PCI)
Description: Ticagrelor for 6-month immediately after PCI to be a part of medication treatment in the Experimental arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg for 6-month (6-month post PCI)
Description: Aspirin for 6-month at 6 months post-PCI (after the discontinuation of the 6-month Ticagrelor treatment) to be a part of medication treatment in the Experimental arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100mg for 12-month (immediately after PCI)
Description: Aspirin for 12-month immediately after PCI to be a part of medication treatment in the Reference arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90mg for 12-month (immediately after PCI)
Description: Ticagrelor for 12-month immediately after PCI to be a part of medication treatment in the Reference arm
Study: NCT05870423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: 18 days olaparib during each cycle of PRRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: 18 days olaparib during each cycle of PRRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: 18 days olaparib during each cycle of PRRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: 18 days olaparib during each cycle of PRRT
Study: NCT05877755

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiac MRI acquisition
Description: All patients will have additional images collected during the magnetic resonance imaging (MRI) examination. These are high-resolution multi-contrast cardiac MRI sequences in gradient echo or in balanced steady state free precession with synchronization on the electrocardiogram. The acquisitions last between 1 minute and 10 minutes. This duration depends on the patient's heart rate and breathing rate. The imaging protocol will last approximately 50 minutes. MRI examinations will be performed on a 1.5 Tesla clinical system with specific cardiac imaging coils.
Study: NCT05180461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emodepside
Description: emodepside tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emodepside
Description: emodepside tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emodepside
Description: emodepside tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emodepside
Description: emodepside tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emodepside
Description: emodepside tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emodepside
Description: emodepside tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emodepside
Description: emodepside tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo of emodepside
Description: emodepside matching placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: matching placebo of emodepside
Description: emodepside matching placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivermectin
Description: ivermectin tablet (overencapsulated for blinding)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matching placebo of ivermectin
Description: matching placebo of overencapsulated ivermectin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matching placebo of ivermectin
Description: matching placebo of overencapsulated ivermectin tablet
Study: NCT06115538

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa
Description: Levodopa benserazide (100+25 mg) will be given to one group of study patients, and levodopa carbidopa entacapone (100+25+200 mg) will be given to the other group of study patients. Just before the drugs are given (0th minute), at 90 and 180 minutes after the drugs are given, a total of 3 doses will be given.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa
Description: Levodopa benserazide (100+25 mg) will be given to one group of study patients, and levodopa carbidopa entacapone (100+25+200 mg) will be given to the other group of study patients. Just before the drugs are given (0th minute), at 90 and 180 minutes after the drugs are given, a total of 3 doses will be given.
Study: NCT04705259

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Antimicrobial Stewardship ENGAGEMENT bundle
Description: Given that a single intervention is unlikely to be effective in stewardship programs, nor in care improvement processes at RACFs \[7\], this trial will deliver a set of multimodal, multidisciplinary interventions to optimise antibiotic use in RACFs. This RACF AMS ENGAGEMENT bundle will comprise the following key interventions:~* Education and engagement of prescribers, nurses, pharmacists and residents and family members~* Nursing initiatives to improve UTI diagnosis and reduce inappropriate urine testing~* Guideline development specific to antibiotic use in RACF residents~* Antimicrobial stewardship team creation in RACF with GP involvement~* EMergency department liaison and use of clinical pathways to ensure consistency of practice across the care continuum~* ElectroNic decision support to guide RACF urine testing and GP antibiotic prescribing~* Telehealth support for key intervention components
Study: NCT04930562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN101
Description: BN101 is an orally ROCK2 selective inhibitor
Study: NCT06509880

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Adenorine
Description: The immunostimulating effect of the drug is associated with its ability to activate the cells of the monocyte-macrophage system, thus increasing the functional activity of all parts of the body, stimulating the repair and regeneration of cells and tissues. It reduces the symptoms of the iflammatory process, stimulates the development of granulations and growth of epithelial tissues, accelerates the process of cleansing and healing of infected wounds. While with healthy people, it can be used as a phylactic drug that improves immunity protection. It was proved that when the drug is used externally, activation of macrophages occurs, thus accelerating wound cleansing process and stimulating reparative processes. In cases when thermal injury to the skin is more than 15-20% of the surface, there is a stress syndrome that suppresses the immune system. When exposed to DNA-Na, lymphocyte activation occurs, wound cleansing processes are accelerated.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04909099

Intervention type: OTHER
Intervention: Standard treatment
Description: Participants shall fill the EARS-Ar questionnaire three times within one month in addition to other questionnaires including the Roland Morris Disability Questionnaire (RMDQ) for low back pain (LBP) patients, and the Knee injury and Osteoarthritis Outcome Score (KOOS) for knee OA patients, in addition to the Fear-Avoidance Beliefs Questionnaire (FABQ), the Numeric Pain Rating Scale (NPRS), and the Global Rating of Change Scale (GRoC).~The first time will be one week after enrolling in the study and receiving the prescribed home exercise program. the second time will be 3-6 days later to test the reliability of the EARS-Ar. After another week, participants will refill the EARS-Ar and the GRoC to test responsiveness.
Study: NCT05512598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0034
Description: HB0034, a single dose
Study: NCT05167162

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: State-Trait Anxiety Questionnaire
Description: The scale measures ordinally (1 to 5) the values observed during exposure to anxiety patterns during exercise, such as higher repetitions, greater weight gain or longer exercise duration, as follows:~1. Not at all~2. Little~3. Sometimes~4. Almost always~5. Always
Study: NCT06509880

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: FOLFOX regimen
Description: (Day 1-2: Oxaliplatin 100 mg/m2 IV infusion, given as a 120 minutes IV infusion in 500 mL D5W, concurrent with leucovorin 400 mg/m2 (or levoleucovorin 200 mg/m2) IV infusion, followed by 5-FU 400 mg/m2 IV bolus, followed by 46-hour 5-FU infusion (2400 mg/m2 for first two cycles, and may be increased to 3000 mg/m2 if tolerated by patient (no toxicity \> grade 1 during the first two cycles), days 3-14: Rest days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: (Day 1-2: Oxaliplatin 100 mg/m2 IV infusion, given as a 120 minutes IV infusion in 500 mL D5W, concurrent with leucovorin 400 mg/m2 (or levoleucovorin 200 mg/m2) IV infusion, followed by 5-FU 400 mg/m2 IV bolus, followed by 46-hour 5-FU infusion (2400 mg/m2 for first two cycles, and may be increased to 3000 mg/m2 if tolerated by patient (no toxicity \> grade 1 during the first two cycles), days 3-14: Rest days)
Study: NCT05167162

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: State-Trait Anxiety Questionnaire
Description: The scale measures ordinally (1 to 5) the values observed during exposure to anxiety patterns during exercise, such as higher repetitions, greater weight gain or longer exercise duration, as follows:~1. Not at all~2. Little~3. Sometimes~4. Almost always~5. Always

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: State-Trait Anxiety Questionnaire
Description: The scale measures ordinally (1 to 5) the values observed during exposure to anxiety patterns during exercise, such as higher repetitions, greater weight gain or longer exercise duration, as follows:~1. Not at all~2. Little~3. Sometimes~4. Almost always~5. Always

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: State-Trait Anxiety Questionnaire
Description: The scale measures ordinally (1 to 5) the values observed during exposure to anxiety patterns during exercise, such as higher repetitions, greater weight gain or longer exercise duration, as follows:~1. Not at all~2. Little~3. Sometimes~4. Almost always~5. Always

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rating of Perceived Exertion
Description: The scale measures in ordinal form (1 to 6) the perceived effort during the exercise as follows:~1. No pain~2. Little pain~3. Moderate~4. Severe~5. Very strong~6. Unbearable

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rating of Perceived Exertion
Description: The scale measures in ordinal form (1 to 6) the perceived effort during the exercise as follows:~1. No pain~2. Little pain~3. Moderate~4. Severe~5. Very strong~6. Unbearable

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rating of Perceived Exertion
Description: The scale measures in ordinal form (1 to 6) the perceived effort during the exercise as follows:~1. No pain~2. Little pain~3. Moderate~4. Severe~5. Very strong~6. Unbearable

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rating of Perceived Exertion
Description: The scale measures in ordinal form (1 to 6) the perceived effort during the exercise as follows:~1. No pain~2. Little pain~3. Moderate~4. Severe~5. Very strong~6. Unbearable
Study: NCT05066360

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: serum antimullerian hormone
Description: serum antimullerian hormone will be analyzed for all participants

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: serum antimullerian hormone
Description: serum antimullerian hormone will be analyzed for all participants
Study: NCT05446558

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis
Description: Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.~Device:~Use of an Echelon Endopatch Powered Device to perform an ileocolonic side-to-side anastomosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal anastomosis
Description: A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Stapler.~Device:~Use of a Proximate Linear Cutter device to perform a side-to-side ileo-colonic anastomosis.Use of a Proximate stapler to the closure of the defect associated with the creation of the side-to-side ileo-colonic anastomosis.
Study: NCT05167162

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Motor coordination tests
Description: The motor coordination tests are divided into three:~1. Jumping with 2 feet together.~2. Throwing 2 balls from a given distance and space.~3. Proprioception turns
Study: NCT06145945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Ropivacaine
Description: 20ml 0.5% ropivacaine is sprayed intraperitoneally
Study: NCT06145945

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 20ml saline is sprayed intraperitoneally
Study: NCT05167162

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Motor coordination tests
Description: The motor coordination tests are divided into three:~1. Jumping with 2 feet together.~2. Throwing 2 balls from a given distance and space.~3. Proprioception turns

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Motor coordination tests
Description: The motor coordination tests are divided into three:~1. Jumping with 2 feet together.~2. Throwing 2 balls from a given distance and space.~3. Proprioception turns

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapeutic intervention
Description: Participants received one session per week, until a total of 20 sessions were completed: Group 1 (n=20) received the muscle compression treatment. Group 2 (n=20) received the manual massage treatment. Group 3 (n=20) received the hydrotherapy treatment and group 4 (n=20) received the active recovery treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapeutic intervention
Description: Participants received one session per week, until a total of 20 sessions were completed: Group 1 (n=20) received the muscle compression treatment. Group 2 (n=20) received the manual massage treatment. Group 3 (n=20) received the hydrotherapy treatment and group 4 (n=20) received the active recovery treatment.